New Prostate Cancer Biomarkers Can Improve Precision Therapy
Improvements are on the horizon in the treatment of prostate cancer that could improve future therapy.
Long-term data show a local disease recurrence rate of 2.1% at 10 years.
Among prostate cancer patients, androgen deprivation therapy (ADT) recipients are 34% more likely to experience any osteoporotic fracture than those who do not receive ADT.
New findings could help explain why men of African ancestry are more likely than white men to die from prostate cancer.